Sugi Predict

Sugi Predict / Compounds / SCHEMBL2184876

SCHEMBL2184876

SCHEMBL2184876

COC(=O)/C=C/c1cccnc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.67
▸ MAPT P10636 3/20 0.67
▸ RAB9A P51151 3/20 0.67
▸ NPC1 O15118 2/20 0.67
▸ JUN P05412 1/20 0.67
▸ NFKB1 P19838 1/20 0.67
▸ MAPK1 P28482 1/20 0.67
▸ GPR55 Q9Y2T6 1/20 0.67
▸ CYP1A1 P04798 7/20 0.61
▸ CYP1A2 P05177 7/20 0.61
▸ CYP1B1 Q16678 7/20 0.61
▸ LMNA P02545 3/20 0.60
▸ PFKFB3 Q16875 1/20 0.58
▸ HTT P42858 1/20 0.57
▸ APAF1 O14727 1/20 0.56
▸ POLB P06746 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ CYP3A4 P08684 2/20 0.56
▸ CYP2D6 P10635 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16585159 1.00 KDM4E (0.67) KDM4EMAPTRAB9ANPC1JUN
SCHEMBL2184878 1.00 KDM4E (0.67) KDM4EMAPTRAB9ANPC1JUN
SCHEMBL27470412 0.89 KDM4E (0.54) KDM4EMAPTRAB9ANPC1JUN
SCHEMBL27470413 0.89 KDM4E (0.54) KDM4EMAPTRAB9ANPC1JUN
SCHEMBL21001847 0.86 RAB9A (0.71) KDM4EMAPTRAB9ANPC1JUN
SCHEMBL27515328 0.83 SMN1; SMN2 (0.56) KDM4EMAPTRAB9ANPC1JUN
SCHEMBL5852187 0.83 RAB9A (0.61) KDM4EMAPTRAB9ANPC1JUN
SCHEMBL13957158 0.83 RAB9A (0.61) KDM4EMAPTRAB9ANPC1JUN
SCHEMBL30012000 0.83 RAB9A (0.61) KDM4EMAPTRAB9ANPC1JUN
SCHEMBL30930826 0.83 RAB9A (0.61) KDM4EMAPTRAB9ANPC1JUN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025101944-A1 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A Plexium, Inc. (US) 2025-05-15 — — WO disclosed
US-20240217932-A1 PYRIDIUM ESTERS THE PROCTER AND GAMBLE COMPANY 2024-07-04 — — US disclosed
CN-118215313-A Photovoltaic cell containing volatile solid additive and preparation method thereof 中国科学院长春应用化学研究所 2024-06-18 — — CN disclosed
US-20230285372-A1 Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives MEDCURIUS INC. (CN) 2023-09-14 — — US disclosed
US-20230285372-A1 Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives MEDCURIUS INC. (CN) 2023-09-14 — — US disclosed
WO-2021259143-A1 PHARMACEUTICAL USE OF (E)-3-ARYLHETEROCYCLYL PROP-2-ENOIC ACID DERIVATIVES 上海长车生物科技有限公司 2021-12-30 — — WO disclosed
US-10364256-B2 Biaryl pyrazoles as NRF2 regulators GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-07-30 — — US disclosed
US-10364256-B2 Biaryl pyrazoles as NRF2 regulators GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-07-30 — — US disclosed
US-20180282349-A1 BIARYL PYRAZOLES AS NRF2 REGULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-10-04 — — US disclosed
US-9994558-B2 Multicyclic compounds and methods of using same Karyopharm Therapeutics Inc. (US) 2018-06-12 — — US disclosed
US-5624922-A Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents STERLING WINTHROP INC. (US) 1997-04-29 — — US disclosed
EP-0597540-B1 Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents STERLING WINTHROP INC (US) 1996-06-05 — — EP disclosed
EP-0691971-A1 7-AZABICYCLO- 2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS UNIVERSITY OF VIRGINIA (US) 1996-01-17 — — EP disclosed
US-5428168-A Substituted butyrolactol ether derivative BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1995-06-27 — — US disclosed
US-5380721-A Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents STERLING WINTHROP INC. (US) 1995-01-10 — — US disclosed
WO-1994022868-A1 7-AZABICYCLO-[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS UNIVERSITY OF VIRGINIA (US) 1994-10-13 — — WO disclosed
EP-0597540-A1 Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents STERLING WINTHROP INC. (US) 1994-05-18 — — EP disclosed
EP-0527817-A1 GAMMA-BUTYROLACTOL ETHER DERIVATIVES BRITISH BIO-TECHNOLOGY LIMITED (GB) 1993-02-24 — — EP disclosed
US-5173496-A Antiinflammatory agents ICI PHARMA (FR) 1992-12-22 — — US disclosed
WO-1991017157-A1 GAMMA-BUTYROLACTOL ETHER DERIVATIVES BRITISH BIO-TECHNOLOGY LIMITED (GB) 1991-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217932-A1 PYRIDIUM ESTERS C5, CBR3, CHRM1 KDM4E 1739/4885MAPT 4762/4885RAB9A 3949/4885
US-10364256-B2 Biaryl pyrazoles as NRF2 regulators NFE2L2, KEAP1, NQO1 KDM4E 2962/4885MAPT 2730/4885RAB9A 2634/4885
US-20230285372-A1 Pharmaceutical use of (E)-3-arylheterocyclylprop-2-enoic acid derivatives NFE2L2, NFE2, TXNRD2 KDM4E 3813/4885MAPT 3234/4885RAB9A 1227/4885
US-20180282349-A1 BIARYL PYRAZOLES AS NRF2 REGULATORS NFE2L2, KEAP1, NQO1 KDM4E 2962/4885MAPT 2730/4885RAB9A 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.